Board of Directors
Hanns Pielenz
In Memoriam
Hanns A. Pielenz
Former President of Fibrotec Ventures, LLC
At Promedior, we continue to be inspired by and grateful to Hanns A. Pielenz, founder and former President of Fibrotec Ventures, LLC who served on Promedior's Board of Directors from 2012 until his death in 2013. In his time on Promedior's Board, his wisdom and thoughtfulness helped to guide and shape the company's plans and strategy.

When he was diagnosed with myelofibrosis in 2011, Hanns decided that his legacy would be to develop, fund, and coordinate medical, financial, and visionary business resources to find a cure for this serious, life-limiting disease. It was as part of this tireless quest that Hanns committed his company to a significant investment in Promedior and joined its Board.

We at Promedior are committed to our drug development programs in myleofibrosis and other serious fibrotic diseases, striving to ensure that Hanns' legacy will help advance potential treatments for patients in need.

Board of Directors

Nancy is the Chief Financial Officer of HAP Investment Group, LLC, a family office for the Hanns A. Pielenz family. In this role, she is active in sourcing, negotiating, and managing entrepreneurial investments in real estate in a variety of product types including multifamily, office and industrial; investments in all stages of venture capital; and investments in operating entities in diverse industries. Her background is in banking and finance, and she was a partner in First Union's Private Capital Management Group prior to the formation of HAP Investment Group in 2000. Nancy sits on the Board of Directors of Parata Systems, a Durham, North Carolina pharmaceutical technology company, and is a founder and board member of HAP Innovations, LLC, a medication adherence technology company. She is also a member of the Board of Trustees of St. Mary's School in Raleigh, North Carolina and serves on the Executive Committee. She has a B.S. and an M.B.A. from the University of North Carolina in Chapel Hill.

Amir Nashat is a Managing Partner in Polaris’ Boston office.  He joined Polaris in 2002 and focuses on investments in healthcare, consumer products and energy.

Amir currently represents Polaris as a Director of AgBiomeaTyr PharmaceuticalBIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Promedior PharmaceuticalsScholar Rock, and Selecta Biosciences.  Additionally, Amir has served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals), Receptos (NASDAQ: RCPT), Sun Catalytix (acquired by Lockheed Martin) and served as a Board Observer of GI Dynamics (GID.AX).  In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof and Sun Catalytix Corporation.

Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the Board of the New England Venture Capital Association.  He has been named to the Forbes Midas list of Top 100 Venture Capitalists.

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer.  Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Gus Lawlor has been a managing director of HealthCare Ventures (HCV) since 2000. Mr. Lawlor has over 15 years of experience in the biotechnology industry in finance, business development, mergers and acquisitions, and general management. Prior to joining HCV in 2000, he was previously chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company, which was acquired by Millennium Pharmaceuticals. Before joining LeukoSite, he was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. He was previously a management consultant with KPMG Peat Marwick.  He received a Master's degree in Public and Private Management from Yale University.

Geert-Jan Mulder, MD, co-founded Forbion in 2006, currently serves on the Board of several Forbion portfolio companies for example AM-Pharma (USD 600 million option deal with Pfizer and Exosome Diagnostics Inc. In 2004 Geert-Jan led the firm’s successful investment in bluebird bio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA®(dalfampridine) board panel to evaluate a new clinical endpoint in Multiple Sclerosis; PanGenetics B.V. leading their Series B and sold to Abbott for USD190 million in 2009; and Transave, where supported the company’s clinical development for ARIKAYCE®(liposomal amikacin for inhalation) partly as interim CMO and serving on the Board of Directors till the merger with Insmed (NASDAQ:INSM) in 2010.

Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan received his Medical Degree from the University of Utrecht (NL), spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC) and is a certified Pharmaceutical Physician. He then joined Searle (now Pfizer) working in the field of Arthritis & Pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex®. After transitioning to Byk Gulden (now Takeda) he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e. Daxas® and Alvesco® in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol®.

John H. Friedman is the Founding and Managing Partner of Easton Capital Group. Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, Mr. Friedman was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. Previously, John was an attorney with Sullivan and Cromwell. He holds a JD degree from Yale Law School and a BA degree, magna cum laude and Phi Beta Kappa, from Yale College. Mr. Friedman currently serves on the Boards of Promedior; Trellis Bioscience, where he is Executive Chairman; MedCPU; Within3; TigerText; and Respiratory Motion. He also co-founded Comverse Technology, which grew to $1.2 billion in sales He has served as the co-chairman of the President's Council at the Cold Spring Harbor Laboratory and currently serves as the Vice Chairman of the Columbia University Medical Center Heath Sciences Advisory Council and as a Trustee of The New Museum of Contemporary Art.

An accomplished entrepreneur in the life sciences industry, Mr. Weisman is currently President and Chief Executive Officer at Seventh Sense Biosystems. Prior to joining Seventh Sense, he was the founder, Chairman and Chief Executive Officer of EKR Therapeutics, a specialty pharmaceutical company focused in the hospital critical care market. Mr. Weisman was also co-founder of ESP Pharma where he served as a director in addition to the company's President and Chief Operating Officer until its sale to PDL Biopharma in 2005. He began his career in sales and marketing at Merck and Co., Inc. and later moved to Parke-Davis where he launched that company's diabetes franchise in 1997. Mr. Weisman graduated with a BA in Chemistry from Rutgers University.

Jason Lettmann is a Partner of Lightstone Ventures as well as a Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics, FIRE1, Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, and Vapotherm. Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe.

Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was a board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014) as well as actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), and Evalve (acquired by Abbott Labs). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013 as well as involved with the founding of Zyga Technologies.

Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and healthcare payer sectors. Jason also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.


Promedior's mission is to develop and advance targeted therapeutics to address the significant unmet needs of patients with diseases involving fibrosis.